GlaxoSmithKline (LON:GSK) has been given a GBX 1,450 ($19.52) price objective by Bank of America in a note issued to investors on Wednesday. The firm currently has a “neutral” rating on the stock. Bank of America’s target price suggests a potential upside of 13.46% from the company’s previous close.

A number of other analysts have also weighed in on the company. Morgan Stanley dropped their price objective on GlaxoSmithKline from GBX 1,450 ($19.52) to GBX 1,400 ($18.84) and set an “underweight” rating for the company in a research note on Friday, December 1st. Goldman Sachs Group set a GBX 1,775 ($23.89) price objective on GlaxoSmithKline and gave the company a “buy” rating in a research note on Friday, December 1st. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, November 30th. J P Morgan Chase & Co reaffirmed a “neutral” rating and issued a GBX 1,330 ($17.90) price target on shares of GlaxoSmithKline in a research note on Thursday, November 30th. Finally, UBS raised GlaxoSmithKline to a “buy” rating and set a GBX 1,550 ($20.86) price target for the company in a research note on Monday, November 27th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of GBX 1,577.14 ($21.23).

GlaxoSmithKline (LON GSK) traded down GBX 1 ($0.01) during trading hours on Wednesday, hitting GBX 1,278 ($17.20). The stock had a trading volume of 7,551,539 shares, compared to its average volume of 11,650,000. GlaxoSmithKline has a 52-week low of GBX 1,277.50 ($17.19) and a 52-week high of GBX 1,724.50 ($23.21).

GlaxoSmithKline (LON:GSK) last released its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The firm had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.

In related news, insider Simon Dingemans purchased 1,076 shares of GlaxoSmithKline stock in a transaction dated Thursday, October 12th. The stock was purchased at an average cost of GBX 1,527 ($20.55) per share, for a total transaction of £16,430.52 ($22,113.76). Also, insider Urs Rohner purchased 473 shares of GlaxoSmithKline stock in a transaction dated Wednesday, October 25th. The shares were bought at an average price of GBX 1,518 ($20.43) per share, with a total value of £7,180.14 ($9,663.71). Insiders have bought 1,576 shares of company stock valued at $2,400,376 over the last 90 days.

WARNING: “Bank of America Analysts Give GlaxoSmithKline (GSK) a GBX 1,450 Price Target” was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with's FREE daily email newsletter.